Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 8Recruiting 4Withdrawn 2Unknown 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 6Genitourinary 5Breast 3Plasma cell 2Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Myeloid 1Lymphoid 1Gynecologic 1Endocrine 1

Conditions

Multiple Myeloma 2Sarcoma 1Desmoplastic Small Round Cell Tumor 1Carcinoma 1Adenocarcinoma 1

Interventions

Dexamethasone 48Calcium Dobesilate 20Bortezomib 20Lenalidomide 19Melphalan 16daratumumab 11Cyclophosphamide 11pomalidomide 10elotuzumab 8carfilzomib 8dexamethasone acetate 7pembrolizumab 6ixazomib 6fludarabine phosphate 6dexamethasone 21-phosphate 6venetoclax 5selinexor 5fludarabine 5auricularum 5Filgrastim 5liposomal doxorubicin 4Thalidomide 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4Whole-Body Irradiation 3Vorinostat 3Simvastatin 3Nivolumab 3Mycophenolic Acid 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Injections × Plasma cell × Clear all
NCT01125449 2025-05-18

Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

Situs Cancer Research Center

Phase 2 Withdrawn
Plasma cellSarcoma

Adenocarcinoma, Carcinoma, Multiple Myeloma, Sarcoma, Desmoplastic Small Round Cell Tumor

NCT04288765 2021-07-09

Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma

Grupo Cooperativo de Hemopatías Malignas

Phase 3 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡